Evidence map›Paper›PMID 42626730›Full record

ArticleInflammatory intestinal diseases

Predictive Value of Leucine-Rich Alpha-2 Glycoprotein Levels in Crohn's Disease Treatment.

Mizuki Komai, Shunichi Yanai, Makoto Eizuka, Tomofumi Oizumi, Yosuke Toya, Takayuki Matsumoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mizuki KomaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Shunichi YanaiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Makoto EizukaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Tomofumi OizumiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Yosuke ToyaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.
Takayuki MatsumotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Leucine-rich alpha-2 glycoprotein (LRG) is a novel serum biomarker that correlates with clinical activity of inflammatory bowel disease. It remains unclear whether LRG can predict treatment efficacy in Crohn's disease (CD). The aim of this study was to clarify the appropriate LRG cut-off value for predicting clinical remission of CD and whether pretreatment levels of LRG were associated with 52-week treatment persistence in patients treated with anti-tumor necrosis factor (anti-TNF) agents or ustekinumab. Methods: We retrospectively analyzed correlations between LRG and CRP levels and clinical activity (Crohn's disease activity index [CDAI]). The rates of drug persistence at 52 weeks from the start of treatment were compared between the ustekinumab group and the anti-TNF agent group. Results: The correlation between CDAI and LRG was statistically significant ( Conclusions: The LRG cut-off value for predicting clinical remission was 15.3 µg/mL for the CDAI of <150. Pretreatment levels of LRG may be a candidate marker for the prediction of efficacy in the use of ustekinumab.

Indexed as

Anti-tumor necrosis factor agentCrohn’s diseaseLeucine-rich alpha-2 glycoproteinUstekinumab

Identifiers

PMID42626730
PMCPMC13493115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.